Does Stereotactic Body Radiotherapy Offer Benefit in Localized Prostate Cancer?

Patients with low- to intermediate-risk prostate cancer have a number of potential management options including active surveillance (primarily for low-risk cancer) and surgery or radiotherapy with curative intent. Improvements in radiotherapy technology have enabled 5-fraction stereotactic body radiotherapy (SBRT), which involves administering higher biologic doses per treatment session in fewer total sessions with the goal of reducing therapy-related toxicity while maintaining efficacy.

Investigators conducted an open-label, randomized, phase 3, noninferiority trial in men with clinical stage T1/T2 prostate cancer with a Gleason score of 3+4 or less who had prostate-specific antigen (PSA) values ≤20 ng/mL. Participants received standard-of-…